Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

AmeriCares' Turkey/Iran airlift aid

  • News

Executive Summary

Antibiotics are being donated by four pharmaceutical firms -- Merck Sharp & Dohme (Mefoxin), Lemmon (amoxicillin, cephalexin), Pfizer (Pfizerpen) and Biocraft Labs (ampicillin, cephalexin and cephradine). Also being sent to Kurdish and other Iraqi refugees are three antidiarrheals: Immodium (Johnson & Johnson), Lomotril (Searle), and Kaopectate (Upjohn). Analgesics include J&J's Tylenol products, Sterling's (Glenbrook Labs) Midol, Upjohn's Motrin and Purepac's ibuprofen. Vitamins and other nutritional supplements are also going to the Middle East. The products, along with other medical supplies, are being sent in at least eight separate airlift operations, AmeriCares says. The fifth of these airlifts is tentatively scheduled for April 24. For information on how to donate medicines contact: Steve Norman or Dwain Schenck at AmeriCares: (800) 486-HELP.

Table

View full table

Tags:
Latest Headlines

Experts Urge Action On Regulatory Science Collaboration In Korea

Cancer Trials: FDA Wants Lower Performance Status Eligibility But Primary Analysis Exclusion OK

US FDA's Califf Defends Agency Work On Marijuana Rescheduling, Animal Testing

Overall Survival Is Not A Required Primary Endpoint In All Cancer Trials, US FDA Says

See All
UsernamePublicRestriction

Register

PS019030

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By